Merck Announces KEYTRUDA® (Pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib

By
Justin.choi
-
0
31
Merck announced that the Phase III KEYNOTE-394 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in Asian patients with advanced hepatocellular carcinoma previously treated with sorafenib met its primary endpoint of overall survival.
[Merck]
7992332 {7992332:AAAAAAAA} 1 apa 50 default 1 167312 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
Press Release